The Latest Breaking News from AbbVie

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

The stock market rally had a mixed week, with the Dow Jones hitting a high while Nvidia led a Nasdaq retreat.

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.